Victory Capital Management Inc. Lowers Position in Savara Inc (NASDAQ:SVRA)

Victory Capital Management Inc. cut its stake in Savara Inc (NASDAQ:SVRA) by 92.0% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 11,246 shares of the company’s stock after selling 128,764 shares during the period. Victory Capital Management Inc.’s holdings in Savara were worth $35,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. The Manufacturers Life Insurance Company increased its stake in shares of Savara by 9.0% during the third quarter. The Manufacturers Life Insurance Company now owns 44,956 shares of the company’s stock valued at $191,000 after purchasing an additional 3,706 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its stake in shares of Savara by 14.9% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 36,390 shares of the company’s stock valued at $112,000 after purchasing an additional 4,732 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in shares of Savara by 5.1% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 125,815 shares of the company’s stock valued at $533,000 after purchasing an additional 6,141 shares in the last quarter. SG Americas Securities LLC increased its stake in shares of Savara by 14.0% during the fourth quarter. SG Americas Securities LLC now owns 51,589 shares of the company’s stock valued at $158,000 after purchasing an additional 6,330 shares in the last quarter. Finally, Rhumbline Advisers increased its stake in shares of Savara by 6.8% during the fourth quarter. Rhumbline Advisers now owns 141,425 shares of the company’s stock valued at $434,000 after purchasing an additional 9,041 shares in the last quarter. 87.93% of the stock is currently owned by hedge funds and other institutional investors.

Savara Stock Down 1.4 %

SVRA opened at $2.82 on Monday. The company has a debt-to-equity ratio of 0.13, a quick ratio of 17.70 and a current ratio of 17.70. Savara Inc has a fifty-two week low of $2.26 and a fifty-two week high of $5.34. The firm’s fifty day moving average is $2.73 and its 200 day moving average is $3.30. The stock has a market cap of $483.97 million, a price-to-earnings ratio of -6.56 and a beta of 0.60.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the stock. Wells Fargo & Company assumed coverage on shares of Savara in a research report on Friday, December 20th. They set an “overweight” rating and a $8.00 price target for the company. JMP Securities reiterated a “market outperform” rating and set a $9.00 price target on shares of Savara in a research note on Thursday, December 19th. One analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $8.83.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.